Market Cap 35.13B
Revenue (ttm) 2.25B
Net Income (ttm) -278.16M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -12.37%
Debt to Equity Ratio 0.00
Volume 886,900
Avg Vol 814,516
Day's Range N/A - N/A
Shares Out 130.09M
Stochastic %K 30%
Beta 0.39
Analysts Strong Sell
Price Target $319.15

Latest News on ALNY

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster

Mar 21, 2025, 5:37 PM EDT - 12 days ago

Alnylam Pharmaceuticals Ready To Go With Its Next Blockbuster


Alnylam shares rise on expanded heart drug approval

Mar 21, 2025, 7:34 AM EDT - 12 days ago

Alnylam shares rise on expanded heart drug approval


US FDA approves Alnylam's drug for rare heart condition

Mar 20, 2025, 5:59 PM EDT - 13 days ago

US FDA approves Alnylam's drug for rare heart condition


Alnylam: Waiting For Regulatory Updates In March

Feb 13, 2025, 5:01 PM EST - 6 weeks ago

Alnylam: Waiting For Regulatory Updates In March


Alnylam to Webcast TTR Investor Day

Sep 26, 2024, 8:00 AM EDT - 6 months ago

Alnylam to Webcast TTR Investor Day


Alnylam: HELIOS-B Success Priced In Already

Aug 30, 2024, 12:29 PM EDT - 7 months ago

Alnylam: HELIOS-B Success Priced In Already


What's Next For Alnylam Stock After A 60% Rise In A Week?

Jun 28, 2024, 7:00 AM EDT - 9 months ago

What's Next For Alnylam Stock After A 60% Rise In A Week?


Alnylam CEO on what is next for heart disease drug

Jun 24, 2024, 6:40 PM EDT - 10 months ago

Alnylam CEO on what is next for heart disease drug


Alnylam Stock Soars on Strong Results in Heart Drug Study

Jun 24, 2024, 11:26 AM EDT - 10 months ago

Alnylam Stock Soars on Strong Results in Heart Drug Study